{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:22:19Z","timestamp":1778613739927,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T00:00:00Z","timestamp":1462752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T00:00:00Z","timestamp":1462752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/bmt.2016.84","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T13:42:17Z","timestamp":1462801337000},"page":"1204-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Toxicities of busulfan\/melphalan versus carboplatin\/etoposide\/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma"],"prefix":"10.1038","volume":"51","author":[{"given":"A V","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M B","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N J","family":"Bunin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Bagatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A E","family":"Seif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,9]]},"reference":[{"key":"BFbmt201684_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","volume":"341","author":"KK Matthay","year":"1999","unstructured":"Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165\u20131173.","journal-title":"N Engl J Med"},{"key":"BFbmt201684_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","volume":"14","author":"SG Kreissman","year":"2013","unstructured":"Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 2013; 14: 999\u20131008.","journal-title":"Lancet Oncol"},{"key":"BFbmt201684_CR3","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1200\/JCO.2000.18.13.2567","volume":"18","author":"SA Grupp","year":"2000","unstructured":"Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000; 18: 2567\u20132575.","journal-title":"J Clin Oncol"},{"key":"BFbmt201684_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bmt.2012.276","volume":"48","author":"AE Seif","year":"2013","unstructured":"Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant 2013; 48: 947\u2013952.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201684_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/sj.bmt.1702376","volume":"25","author":"D Valteau-Couanet","year":"2000","unstructured":"Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937\u2013942.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201684_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/bmt.2015.264","volume":"51","author":"C Pasqualini","year":"2015","unstructured":"Pasqualini C, Dufour C, Goma G, Raquin MA, Lapierre V, Valteau-Couanet D . Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients. Bone Marrow Transplant 2015; 51: 227\u2013231.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201684_CR7","doi-asserted-by":"publisher","first-page":"Abstract 2","DOI":"10.1200\/jco.2011.29.18_suppl.2","volume":"29","author":"RL Ladenstein","year":"2011","unstructured":"Ladenstein RL, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1\/SIOPEN trial. J Clin Oncol 2011; 29: Abstract 2.","journal-title":"J Clin Oncol"},{"key":"BFbmt201684_CR8","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1038\/bmt.2008.69","volume":"41","author":"R Ladenstein","year":"2008","unstructured":"Ladenstein R, Potschger U, Hartman O, Pearson AD, Klingebiel T, Castel V et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008; 41: S118\u2013S127.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201684_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/sj.bmt.1701737","volume":"23","author":"O Hartmann","year":"1999","unstructured":"Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789\u2013795.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201684_CR10","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.ejca.2012.05.020","volume":"48","author":"GJ Veal","year":"2012","unstructured":"Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D et al. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1\/SIOPEN trial. Eur J Cancer 2012; 48: 3063\u20133072.","journal-title":"Eur J Cancer"},{"key":"BFbmt201684_CR11","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.bbmt.2013.07.017","volume":"19","author":"CE Dandoy","year":"2013","unstructured":"Dandoy CE, Hirsch R, Chima R, Davies SM, Jodele S . Pulmonary Hypertension after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2013; 19: 1546\u20131556.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201684_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12185-012-1246-z","volume":"97","author":"N Kawashima","year":"2013","unstructured":"Kawashima N, Ikoma M, Sekiya Y, Narita A, Yoshida N, Matsumoto K et al. Successful treatment of pulmonary hypertension with beraprost and sildenafil after cord blood transplantation for infantile leukemia. Int J Hematol 2013; 97: 147\u2013150.","journal-title":"Int J Hematol"},{"key":"BFbmt201684_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/pbc.24405","volume":"60","author":"U Zeilhofer","year":"2013","unstructured":"Zeilhofer U, Ashworth M, Amrolia P, Rao A, Chiesa R, Veys P et al. Pulmonary hypertension following haematopoietic stem cell transplantation for primary haemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2013; 60: 521\u2013523.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbmt201684_CR14","doi-asserted-by":"publisher","first-page":"E185","DOI":"10.1111\/petr.12576","volume":"19","author":"D Ozyoruk","year":"2015","unstructured":"Ozyoruk D, Kibar AE, Surucu M, Azak E, Emir S, Cetin II et al. Pulmonary arterial hypertension in a child with stage-IV neuroblastoma after autologous hematopoietic stem cell transplantation and review of the literature. Pediatr Transplant 2015; 19: E185\u2013E188.","journal-title":"Pediatr Transplant"},{"key":"BFbmt201684_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/pbc.25893","volume":"63","author":"AV Desai","year":"2016","unstructured":"Desai AV, Seif AE, Li Y, Getz K, Fisher BT, Huang V et al. Resource utilization and toxicities after carboplatin\/etoposide\/melphalan and busulfan\/melphalan for autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. Pediatr Blood Cancer 2016; 63: 901\u2013907.","journal-title":"Pediatr Blood Cancer"},{"key":"BFbmt201684_CR16","unstructured":"Children's Oncology Group. ANBL09P1: A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan\/Melphalan (Bu\/Mel) for Newly Diagnosed High-Risk Neuroblastoma. Version 4A; 2013."},{"key":"BFbmt201684_CR17","unstructured":"Children's Oncology Group. ANBL12P1: Pilot Study Using Myeloablative Busulfan\/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma. 2013."},{"key":"BFbmt201684_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/petr.12202","volume":"18","author":"S Soni","year":"2014","unstructured":"Soni S, Pai V, Gross TG, Ranalli M . Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. Pediatr Transplant 2014; 18: 217\u2013220.","journal-title":"Pediatr Transplant"},{"key":"BFbmt201684_CR19","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1200\/JCO.1988.6.12.1874","volume":"6","author":"GM Brodeur","year":"1988","unstructured":"Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874\u20131881.","journal-title":"J Clin Oncol"},{"key":"BFbmt201684_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Int Med 1993; 118: 255\u2013267.","journal-title":"Ann Int Med"},{"key":"BFbmt201684_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778\u2013783.","journal-title":"Transplantation"},{"key":"BFbmt201684_CR22","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","volume":"29","author":"JR Park","year":"2011","unstructured":"Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011; 29: 4351\u20134357.","journal-title":"J Clin Oncol"},{"key":"BFbmt201684_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/sj.bmt.1701994","volume":"24","author":"HC Toh","year":"1999","unstructured":"Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR . Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999; 24: 891\u2013895.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201684_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","volume":"13","author":"E Carreras","year":"2007","unstructured":"Carreras E, Rosinol L, Terol MJ, Alegre A, de Arriba F, Garcia-Larana J et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007; 13: 1448\u20131454.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201684","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:22:20Z","timestamp":1648063340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["BFbmt201684"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.84","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,9]]},"assertion":[{"value":"18 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}